Posts tagged Phase 1
Echelon starts Theralase at speculative buy

Echelon Wealth Partners initiated coverage of Theralase Technologies (TSXV:TLT) with a “speculative buy” rating and one-year price target of 90 cents. The stock closed at 47 cents on Sept. 1.

Read More
Ladenburg starts Molecular Templates at buy

Ladenburg Thalmann initiated coverage of Molecular Templates (NASDAQ:MTEM) with a “buy” rating and $10.00 price target. The stock closed at $5.50 on August 2.

Read More
Leerink starts Mersana at OP

Leerink launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with an “outperform” rating and $23 one-year price target, representing an approximate $500-million valuation. The stock closed at $14.05 on July 21.

Read More
Roth starts Poxel SA at buy

Roth Capital Partners initiated coverage of Poxel SA (NXT:PA) with a “buy” rating and price target of €11. The stock was recently quoted at €5.14.

Read More
Ladenburg starts Cidara at buy

Ladenburg Thalmann launched coverage of Cidara Therapeutics (NASDAQ:CDTX) with a “buy” rating and $11.25 price target. The stock closed at $6.95 on March 11.

Read More
BioTime forms new AgeX unit on human aging

BioTime (NYSE MKT:BTX) has created AgeX Therapeutics, which will consolidate certain BioTime subsidiaries and programs in the field of interventional gerontology.

Read More
RepliCel posts positive RCS-01 interim results

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) reported statistically and clinically significant positive data from an interim analysis of its Phase I study evaluating RCS-01 for the treatment of aging and sun-damaged skin.

Read More
HCW downgrades Proteon to neutral

H.C. Wainwright downgraded Proteon Therapeutics (NASDAQ:PRTO) to “neutral” from “buy” and slashed its price target to $3 from $18, citing a lack of major catalysts that will likely render the shares range-bound. The stock closed at $1.75 on March 16.

Read More
RepliCel hair loss trial meets primary endpoints

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has successfully completed its first-in-human clinical study of the company's autologous cell therapy for the treatment of androgenetic alopecia (pattern baldness).

Read More
BioTime opens U.S. sites in dry AMD trial

BioTime (NYSE MKT:BTX) is expanding its ongoing Phase 1/2a clinical trial for OpRegen in the advanced dry form of AMD by naming the first two sites that will treat patients in the U.S.

Read More
Histogenics cartilage data published

Histogenics (NASDAQ:HSGX) announced the online peer-reviewed publication in the Journal of Orthopaedic Research that analyzes mechanical properties of tissue engineered cartilage based on work done as part of a sponsored-research agreement between Histogenics and Dr. Lawrence Bonassar at Cornell University. 

Read More
Soricimed publishes Phase 1 results of SOR-C13

Closely-held Soricimed Biopharma announced publication in the peer-reviewed journal, Investigational New Drugs, The Journal of New Anticancer Agents of its first-in-human Phase 1 study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Read More
Mass. Life Sciences launches ramp-up program

The Massachusetts Life Sciences Center (MLSC) has launched the Massachusetts Ramp-Up Program (MassRamp), a new program that will provide grant funding to promising early-stage life sciences companies.

Read More
HCW starts Calithera Biosciences at buy

H.C. Wainwright initiated coverage of Calithera Biosciences (NASDAQ:CALA) with a “buy” rating and $9 price target. The stock closed at $3.95 on Jan. 5.

Read More
Ladenburg starts Cellectar Biosciences at buy

Ladenburg Thalmann launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $2.70 price target. The stock closed at $1.24 on Dec. 20.

Read More